Posts

Endevica spinout Kalohexis files confidential IPO to advance obesity drug rivaling GLP-1s

on
Sources: Obesity biotech Kalohexis confidentially files to go public in US Kalohexis files confidential IPO draft registration with SEC Kalohexis Launches from Endevica to Advance Melanocortin ... Endeveco Bio spin-off to launch obesity trial Obesity biotech Kalohexis files confidential IPO - pharmaphorum Weight loss - Articles | BioWorld Obesity Kalohexis launches as spin-out from Endevica Bio | BioWorld Endevica Bio Unveils Differentiated Mechanism for Durable Weight ... Endevica Announces Spinout of Kalohexis to Advance First Targeting the Neuroscience of Human Misery - Bioneex USPTO Publishes Trademark 'KALOHEXIS' for Opposition

MeiraGTx scoops up to $400M from Oberland Capital to push gene therapies toward commercialization

on

Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial

on

US lawmakers intensify scrutiny of Chinese clinical trials, raising industry concerns over cost and disruption

on

Vertex’s $10B deal for Crinetics marks its biggest acquisition to date

on

Compass Pathways Hypes Durability of Psilocybin for Depression Ahead of Year‑End FDA Filing

on

Bristol Myers details Krazati confirmatory study failure in colorectal cancer

on

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting (July 2026)

on

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

on

FDA deepens Vertex's Casgevy label to include patients as young as 2

on

Scribe Therapeutics preps IPO to fund lipid‑lowering genetic medicines through clinical trials

on

Genentech lays off 103 as part of gRED rethink, advances with $490M breast cancer collaboration

on

Novartis to Acquire UK Biotech Myricx Bio for Up to $1.5 Billion to Expand ADC Oncology Pipeline

on